Biotech deals accelerate as patent losses loom

Strategic biotech M&A is regaining steam as Big Pharma looks to offset patent losses and capitalize on improved market conditions.

The big picture: Corporate dealmaking is on pace to rival 2019, the sector's strongest recent year for M&A, per PitchBook data.